On April 19, the reporter learned from Yipinhong that the company's global Phase III clinical trial REDUCE 2 of its innovative gout drug AR882 has recently completed the enrollment of all patients, which means that the domestic and international clinical trials of AR882 have fully entered the critical Phase III stage. The person in charge of the AR882 project research and development told reporters that the data from the global multi-center Phase II clinical trial of AR882 that has been completed showed that compared with existing therapies, AR882 is more effective and safer in treating gout patients. In addition to reducing sUA levels in gout patients, AR882 can also significantly reduce tophi, reduce the burden of uric acid crystals, and reduce the rate of acute gout attacks. This achievement not only fills the gap in global tophi dissolution therapy, but is also listed as a key variety by the Greater Bay Area Branch of the National Medical Products Administration.